Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PneumoSIP

Financiado

Cerrado

PneumoSIP a cost effective solution for the rapid diagnostic of pneumonia

Despite significant advances in sanitation and medicine, infectious diseases still annually claim in excess of 15 million lives. Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Pneumonia i... ver más

28/02/2015

LABORATORIOS ALPHA...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

LABORATORIOS ALPHA SAN IGNACIOP PHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 112K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-02-28

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LABORATORIOS ALPHA SAN IGNAC...

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Pro-Staph-ID Clinical biomarker and rapid diagnostic test for Staphylococ... 71K€ Cerrado

PCIN-2015-223 FABRICACION EN SERIE PILOTO DE DISPOSITIVOS MEDICOS BASADOS... 122K€ Cerrado

PNEUMOSIP PNEUMOSIP 3M€ Cerrado

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

RESPOC Fast cost effective user friendly point of care POC inst... 1M€ Cerrado

C4L Chips for Life 4M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2014-09-30
Fecha Fin: 2015-02-28

Líder del proyecto

LABORATORIOS ALPHA SAN IGNACIOP PHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 112K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite significant advances in sanitation and medicine, infectious diseases still annually claim in excess of 15 million lives. Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Pneumonia is also the leading cause of death in children worldwide. It kills an estimated 1.6 million children under the age of five every year, about 25% of all pediatric deaths around the world – more than AIDS, malaria and tuberculosis combined . In the EU about 3.3 million cases are reported annually with hospitalization rates ranging from 20–50%, meaning that there are about 1 million hospital admissions for CAP per year in the EU . In addition, the growing resistance to antibiotic treatments (>10% in EU), makes pathogen identification and streamlining of antibiotic treatment even more important. AlphaSIP aims the development of a cost-effective solution for the rapid diagnostic of pneumonia. Infectious diseases represent the largest segment of the In-Vitro Molecular Diagnostics Market with nearly 50%. It is a big market that is growing fast: $ 5 B with a 14% CAGR. The Point-of-Care Molecular Diagnostics devices market for infectious diseases based on microfluidics has a size of approximately 900 M $ with an even higher growth rate . PneumoSIP product line is expected to become the main source of growth for the company in the next 5 years. The H2020 SME instrument phase I feasibility study has four main objectives: - To verify with final users (physicians and lab technicians) the features of the problem. - To validate and close the first specifications of the product with final users and customers. - To confirm with updated market studies the future Pn

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores